Nurix Therapeutics (NRIX) Research & Development (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Research & Development for 8 consecutive years, with $87.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Research & Development rose 12.24% year-over-year to $87.7 million; the TTM figure through May 2026 stood at $340.9 million (up 26.06% YoY), while the FY2025 annual figure was $316.9 million, up 42.99% from the prior year.
• Research & Development rose to $87.7 million in Q2 2026 per NRIX's latest filing, from $84.1 million in the prior quarter.
• Across five years, Research & Development topped out at $87.7 million in Q2 2026 and bottomed at $43.1 million in Q1 2022.
• Historically, Research & Development has averaged $60.2 million across 5 years, with a median of $49.9 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development soared 87.53% — and 2023, when it dropped 3.64%.
• Nurix Therapeutics' Research & Development stood at $46.1 million in 2022, then increased by 7.82% to $49.7 million in 2023, then jumped by 35.22% to $67.2 million in 2024, then climbed by 23.5% to $83.0 million in 2025, then advanced by 5.58% to $87.7 million in 2026.
• Business Quant data shows NRIX's Research & Development at $87.7 million in Q2 2026, $84.1 million in Q1 2026, and $83.0 million in Q4 2025.